Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI response largely asserts sleep-aid interactions with Lipitor that are not described in the FDA label; two statements contradict the labeling, and one claim is only partially supported. Overall, the claims do not align well with the labeling and extrapolate beyond what is supported.
Category Scores
MonitoringRecommendations
46
Accurate Statements
Avoid combining Lipitor with other CYP3A4 inhibitors like grapefruit juice.
Grapefruit Juice (7.2) indicates CYP3A4 inhibition; labeling notes interactions with atorvastatin (7.1).
Avoid combining Lipitor with other CYP3A4 inhibitors like grapefruit juice.
Grapefruit Juice (7.2) indicates CYP3A4 inhibition; labeling notes interactions with atorvastatin (7.1).
Grapefruit juice can increase atorvastatin exposure via CYP3A4 inhibition.
7.2 Grapefruit Juice; 7.1 Drug Interactions; Table 3 in 12.3 discusses co-administered drugs and PK effects.
Unsupported Statements
Lipitor (atorvastatin) can affect the effectiveness of sleep aids through pharmacokinetic interactions.
Not described in labeling.
Lipitor inhibits CYP3A4 enzymes in the liver.
Label indicates atorvastatin is metabolized by CYP3A4 and can be increased by strong CYP3A4 inhibitors; does not state that atorvastatin inhibits CYP3A4.
CYP3A4 enzymes metabolize many drugs.
General pharmacology; not a labeling assertion specific to Lipitor interactions.
Inhibiting CYP3A4 can raise blood levels of sleep aids processed by this pathway.
Label discusses CYP3A4 inhibitors increasing statin levels, not sleep aids; no sleep-aid–specific PK claim.
Elevated levels of sleep aids can amplify sedative effects.
Sleep-aid–specific sedation changes are not described in Lipitor labeling.
Elevated levels of sleep aids can alter efficacy, depending on the sleep aid.
No label statement about sleep-aid efficacy changes due to atorvastatin.
Z-drugs (zolpidem, zaleplon, eszopiclone) have a moderate interaction risk with Lipitor.
Label does not categorize Z-drug interactions with atorvastatin.
Elevated levels of Z-drugs can increase drowsiness, dizziness, or next-day impairment.
Sleep-aid–related sedation is not described as a Lipitor-specific labeling assertion.
Elevated levels of Z-drugs can indirectly reduce perceived effectiveness if side effects limit use.
No labeling statement about sleep-aid efficacy changes with atorvastatin.
Lipitor significantly boosts concentrations of benzodiazepines such as triazolam or midazolam.
No labeling assertion that atorvastatin markedly boosts benzodiazepine levels.
This boost in benzodiazepine concentrations enhances sedation.
Not described in Lipitor labeling.
This boost in benzodiazepine concentrations risks tolerance or reduced reliability over time.
Not described in Lipitor labeling.
Ramelteon (Rozerem) has minimal interaction with Lipitor, as it is less dependent on CYP3A4.
Not described in Lipitor labeling.
Diphenhydramine (Benadryl) or melatonin have no significant interaction with Lipitor; they follow different metabolic paths.
Not described in Lipitor labeling.
No major issues reported with doxepin or suvorexant when used with Lipitor, though monitoring is advised.
Not described in Lipitor labeling.
Lipitor competitively inhibits CYP3A4.
Atorvastatin is a substrate, not an inhibitor of CYP3A4.
Lipitor slows breakdown of substrate sleep aids.
Not described in Lipitor labeling.
Higher plasma concentrations occur when sleep aids are processed by CYP3A4.
Not described in Lipitor labeling.
For zolpidem, levels can rise 1.5-2 fold.
No labeling statement specifying zolpidem concentration changes with atorvastatin.
Higher concentrations prolong half-life of sleep aids.
Not described in Lipitor labeling.
Higher concentrations intensify the effects of sleep aids.
Not described in Lipitor labeling.
Clinical studies show CYP3A4-mediated interactions with sleep aids in healthy volunteers.
Label does not present sleep-aid–specific study data for atorvastatin.
There is greater impact of the interaction in elderly or liver-impaired patients.
Label discusses elderly and hepatic considerations for statins generally, but not explicitly for sleep-aid interactions with atorvastatin.
Start with the lowest effective sleep aid dose when on Lipitor.
Label does not provide sleep-aid–specific dosing guidance in the context of Lipitor.
Space doses if possible (e.g., take Lipitor in the evening and the sleep aid earlier).
Not described in Lipitor labeling.
Regular monitoring for excessive sedation when combining Lipitor with sleep aids.
Label emphasizes general monitoring for drug interactions; sleep-aid–specific sedation monitoring is not explicitly described.
Consider switching to non-CYP3A4 sleep aids like melatonin if issues arise.
Not stated in Lipitor labeling.
Ambien (zolpidem) with Lipitor can cause amplified grogginess or 'hangover' effects.
Not described in Lipitor labeling.
Dose reductions or switches are sometimes prompted by Ambien + Lipitor interactions.
Label does not provide Ambien-specific guidance with atorvastatin.
Rare cases of reduced sleep aid response due to statin-induced insomnia.
No labeling assertion about statin-induced insomnia affecting sleep aids.
Statins occasionally disrupt sleep independently.
Label does not universally state this for all statins; atorvastatin-specific sleep disruption is not emphasized in the labeling.
Contradictions
Low
AI Statement
Lipitor inhibits CYP3A4 enzymes in the liver.
Label Reference
7.1, 12.3
Low
AI Statement
Lipitor competitively inhibits CYP3A4.
Label Reference
12.3
Important Omissions
No sleep-aid–specific pharmacokinetic interaction data (e.g., zolpidem, zaleplon, eszopiclone) described in Lipitor labeling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct sleep-aid interactions are described in the Lipitor label; interactions described are general CYP3A4 interactions with statins rather than sleep aids.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Most claims refer to sleep-aid interactions that are not described in the Lipitor label; two statements contradict the label.
Suggested Improvement
Limit claims to labeling-supported interactions; clearly distinguish atorvastatin PK interactions (with CYP3A4 inhibitors) from sleep-aid-specific effects; remove extrapolations about sleep efficacy, dosing strategies, and non-label sleep aids.